Acurx Pharmaceuticals Inc
Company Profile
Business description
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
Contact
259 Liberty Avenue
Staten IslandNY10305
USAT: +1 917 533-1469
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
4
Stocks News & Analysis
stocks
Fair value upgrade for this ASX income player
stocks
The SpaceX IPO and the Elon Musk factor
stocks
The ASX’s most shorted stocks in 2026
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,657.50 | 2.20 | 0.03% |
| CAC 40 | 7,772.45 | 70.50 | 0.92% |
| DAX 40 | 22,562.88 | 262.13 | 1.18% |
| Dow JONES (US) | 45,206.54 | 39.90 | 0.09% |
| FTSE 100 | 10,127.96 | 160.61 | 1.61% |
| HKSE | 24,750.79 | 201.09 | -0.81% |
| NASDAQ | 20,760.43 | 187.93 | -0.90% |
| Nikkei 225 | 51,885.85 | 1,487.22 | -2.79% |
| NZX 50 Index | 12,748.92 | 186.47 | -1.44% |
| S&P 500 | 6,337.46 | 31.39 | -0.49% |
| S&P/ASX 200 | 8,461.00 | 0.10 | 0.00% |
| SSE Composite Index | 3,923.29 | 9.56 | 0.24% |